Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 3548 Download: 171 Web of Science: 8 Crossref: 8

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 3549 Download: 135 Web of Science: 4 Crossref: 4

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2017;23(1):1-12. Published online March 9, 2017

DOI: https://doi.org/10.3350/cmh.2016.0109

View: 17682 Download: 602 Web of Science: 145 Crossref: 145

1 |

Viewed By 5301	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5246	MAFLD: How is it different from NAFLD?
Viewed By 5150	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3862	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3801	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search